pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CKFA115A12101
Phase 1 · other · Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma
CKFA115A12101 for Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma is a Phase 1 program (other) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CKFA115A12101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Modality
- other
- Indication
- Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma
- Status
- active
- Trials
- 1